Entinostat, nivolumab and ipilimumab for women with advanced HER2-negative breast cancer: a phase Ib trial-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Entinostat, nivolumab and ipilimumab for women with advanced HER2-negative breast cancer: a phase Ib trial

Published:2024-02-14 Issue:6 Volume:5 Page:866-879
ISSN:2662-1347
Container-title:Nature Cancer
language:en
Short-container-title:Nat Cancer

Author:

Roussos Torres Evanthia.T.^ORCID,Ho Won J.^ORCID,Danilova Ludmila,Tandurella Joseph A.^ORCID,Leatherman James,Rafie Christine,Wang Chenguang,Brufsky Adam^ORCID,LoRusso Patricia^ORCID,Chung Vincent,Yuan Yuan,Downs Melinda,O’Connor Ashley,Shin Sarah M.,Hernandez Alexei,Engle Elizabeth L.^ORCID,Piekarz Richard,Streicher Howard,Talebi Zahra^ORCID,Rudek Michelle A.^ORCID,Zhu Qingfeng^ORCID,Anders Robert A.^ORCID,Cimino-Mathews Ashley^ORCID,Fertig Elana J.^ORCID,Jaffee Elizabeth M.^ORCID,Stearns Vered,Connolly Roisin M.^ORCID

Funder

Tower Cancer Research Foundation

Concern Foundation

METAvivor

V Foundation for Cancer Research

Commonwealth Foundation

U.S. Department of Health & Human Services | NIH | National Cancer Institute

Breast Cancer Research Foundation

Mary Kay Foundation

Publisher

Springer Science and Business Media LLC

Link

https://www.nature.com/articles/s43018-024-00729-w.pdf

Reference63 articles.

1. Ribas, A. & Wolchok, J. D. Cancer immunotherapy using checkpoint blockade. Science 359, 1350–1355 (2018).

2. Pardoll, D. M. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12, 252–264 (2012).

3. Stanton, S. E., Adams, S. & Disis, M. L. Variation in the incidence and magnitude of tumor-infiltrating lymphocytes in breast cancer subtypes: a systematic review. JAMA Oncol. 2, 1354–1360 (2016).

4. Vikas, P., Borcherding, N. & Zhang, W. The clinical promise of immunotherapy in triple-negative breast cancer. Cancer Manag. Res. 10, 6823–6833 (2018).

5. Agarwala, S. S. et al. Efficacy and safety of entinostat (ENT) and pembrolizumab (PEMBRO) in patients with melanoma progressing on or after a PD-1/L1 blocking antibody. J. Clin. Oncol. 36, 9530 (2018).

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The treatment landscape of triple-negative breast cancer;Medical Oncology;2024-08-29

2. Towards targeting the breast cancer immune microenvironment;Nature Reviews Cancer;2024-07-05

3. Cell of origin alters myeloid-mediated immunosuppression in lung adenocarcinoma;2024-06-23

4. Virtual patient analysis identifies strategies to improve the performance of predictive biomarkers for PD-1 blockade;2024-05-21

5. Modulation of the tumor microenvironment and mechanism of immunotherapy-based drug resistance in breast cancer;Molecular Cancer;2024-05-07

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3